Journal Article

DKFZ-2020-01158

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Clinical and pathological associations of PTEN expression in ovarian cancer: a multicentre study from the Ovarian Tumour Tissue Analysis Consortium.

Martins, F. C. ; Couturier, D.-L. ; Paterson, A. ; Karnezis, A. N. ; Chow, C. ; Nazeran, T. M. ; Odunsi, A. ; Gentry-Maharaj, A. ; Vrvilo, A. ; Hein, A. ; Talhouk, A. ; Osorio, A. ; Hartkopf, A. D. ; Brooks-Wilson, A. ; DeFazio, A. ; Fischer, A. ; Hartmann, A. ; Hernandez, B. Y. ; McCauley, B. M. ; Karpinskyj, C. ; de Sousa, C. B. ; Høgdall, C. ; Tiezzi, D. G. ; Herpel, E. ; Taran, F. A. ; Modugno, F. ; Keeney, G. ; Nelson, G. ; Steed, H. ; Song, H. ; Luk, H. ; Benitez, J. ; Alsop, J. ; Koziak, J. M. ; Lester, J. ; Rothstein, J. H. ; de Andrade, J. M. ; Lundvall, L. ; Paz-Ares, L. ; Robles-Díaz, L. ; Wilkens, L. R. ; Garcia, M. J. ; Intermaggio, M. P. ; Alcaraz, M.-L. ; Brett, M. A. ; Beckmann, M. W. ; Jimenez-Linan, M. ; Anglesio, M. ; Carney, M. E. ; Schneider, M. ; Traficante, N. ; Pejovic, N. ; Singh, N. ; Le, N. ; Sinn, P. ; Ghatage, P. ; Erber, R. ; Edwards, R. ; Vierkant, R. ; Ness, R. B. ; Leung, S. ; Orsulic, S. ; Brucker, S. Y. ; Kaufmann, S. H. ; Fereday, S. ; Gayther, S. ; Winham, S. J. ; Kommoss, S. ; Pejovic, T. ; Longacre, T. A. ; McGuire, V. ; Rhenius, V. ; Sieh, W. ; Shvetsov, Y. B. ; Whittemore, A. S. ; Staebler, A. ; Karlan, B. Y. ; Rodriguez-Antona, C. ; Bowtell, D. D. ; Goode, E. L. ; Høgdall, E. ; Candido Dos Reis, F. J. ; Gronwald, J. ; Chang-Claude, J.DKFZ* ; Moysich, K. B. ; Kelemen, L. E. ; Cook, L. S. ; Goodman, M. T. ; Fasching, P. A. ; Crawford, R. ; Deen, S. ; Menon, U. ; Huntsman, D. G. ; Köbel, M. ; Ramus, S. J. ; Pharoah, P. D. P. ; Brenton, J. D.

2020
Nature Publ. Group Edinburgh

This record in other databases:  

Please use a persistent id in citations: doi:10.1038/s41416-020-0900-0

Abstract: PTEN loss is a putative driver in histotypes of ovarian cancer (high-grade serous (HGSOC), endometrioid (ENOC), clear cell (CCOC), mucinous (MOC), low-grade serous (LGSOC)). We aimed to characterise PTEN expression as a biomarker in epithelial ovarian cancer in a large population-based study.Tumours from 5400 patients from a multicentre observational, prospective cohort study of the Ovarian Tumour Tissue Analysis Consortium were used to evaluate associations between immunohistochemical PTEN patterns and overall survival time, age, stage, grade, residual tumour, CD8+ tumour-infiltrating lymphocytes (TIL) counts, expression of oestrogen receptor (ER), progesterone receptor (PR) and androgen receptor (AR) by means of Cox proportional hazard models and generalised Cochran-Mantel-Haenszel tests.Downregulation of cytoplasmic PTEN expression was most frequent in ENOC (most frequently in younger patients; p value = 0.0001) and CCOC and was associated with longer overall survival in HGSOC (hazard ratio: 0.78, 95% CI: 0.65-0.94, p value = 0.022). PTEN expression was associated with ER, PR and AR expression (p values: 0.0008, 0.062 and 0.0002, respectively) in HGSOC and with lower CD8 counts in CCOC (p value < 0.0001). Heterogeneous expression of PTEN was more prevalent in advanced HGSOC (p value = 0.019) and associated with higher CD8 counts (p value = 0.0016).PTEN loss is a frequent driver in ovarian carcinoma associating distinctly with expression of hormonal receptors and CD8+ TIL counts in HGSOC and CCOC histotypes.

Note: 2020 Sep;123(5):793-802

---

Contributing Institute(s):

1. C020 Epidemiologie von Krebs (C020)

Research Program(s):

1. 313 - Cancer risk factors and prevention (POF3-313) (POF3-313)

Appears in the scientific report 2020

---

Database coverage:
; BIOSIS Previews ; Biological Abstracts ; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; Current Contents - Life Sciences ; Ebsco Academic Search ; Essential Science Indicators ; IF >= 5 ; JCR ; NCBI Molecular Biology Database ; PubMed Central ; SCOPUS ; Science Citation Index ; Science Citation Index Expanded ; Web of Science Core Collection

---